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Abstract
 
Amongst the many ploys used by microbial pathogens to interfere with host immune responses
is the production of proteins with the properties of superantigens. These properties enable su-
perantigens to interact with conserved variable region framework subdomains of the antigen
receptors of lymphocytes rather than the complementarity determining region involved in the
binding of conventional antigens. To understand how a B cell superantigen affects the host
immune system, we infused protein A of 
 
Staphylococcus aureus
 
 (SpA) and followed the fate of
peripheral B cells expressing B cell receptors (BCRs) with V
 
H 
 
regions capable of binding SpA.
Within hours, a sequence of events was initiated in SpA-binding splenic B cells, with rapid
down-regulation of BCRs and coreceptors, CD19 and CD21, the induction of an activation
phenotype, and limited rounds of proliferation. Apoptosis followed through a process heralded
by the dissipation of mitochondrial membrane potential, the induction of the caspase pathway,
and DNA fragmentation. After exposure, B cell apoptotic bodies were deposited in the spleen,
lymph nodes, and Peyer’s patches. Although in vivo apoptosis did not require the Fas death re-
ceptor, B cells were protected by interleukin (IL)-4 or CD40L, or overexpression of Bcl-2.
These studies define a pathway for BCR-mediated programmed cell death that is V
 
H 
 
region
targeted by a superantigen.
Key words: tolerance • repertoire • clonal selection • Ig genes • host immunity
 
Introduction
 
The fate of a B lymphocyte clone is largely determined by
signals received through the Ag receptor (i.e., B cell recep-
tor [BCR]
 
*
 
). The developmental and maturational stage of
the lymphocyte, the availability of costimulatory signals,
and the qualitative features of the BCR signal influence the
cellular outcome of these ligand exposures. Antigenic
challenge can result, therefore, in either positive selection
due to proliferation and pro-survival affects or negative se-
lection due to functional inactivation, deletion, or induc-
tion of BCR editing. However, a B cell can be affected by
encounters with more than one type of Ag, as the BCR of
a clone might be cross-reactive with unrelated exogenous
and self-ligands. Such cross-reactivity has been said to con-
tribute to the primary mode of action of natural viral and
bacterial proteins that have been termed superantigens for
their capacity to interact with conserved sites in the vari-
able regions. Consequently, interactions with superantigens
are orders of magnitude more frequent in the lymphocyte
repertoire than those for a conventional Ag that typically
involve CDRs (for review see 1).
 
In recent studies, we have shown that protein A of 
 
Staph-
ylococcus aureus
 
 (SpA) has the properties of a B cell superan-
tigen by virtue of interactions with a large supraclonal B
cell set via high affinity framework-mediated interactions
with soluble and cell-associated BCR (1). Crystallographic
studies have demonstrated that a domain of SpA forms a
complex with human Fab via a conformational surface on
BCR that involves side chains from four 
 
  
 
strands present
in framework subdomains of the clan III gene-encoded V
 
H
 
region (2). These binding interactions and the B cell target-
ing properties of SpA do not involve the site by which SpA
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Fax: 858-534-5399; E-mail: gsilverman@ucsd.edu
 
*
 
Abbreviations used in this paper: 
 
AICD, activation-induced cell death;
BCR, B cell receptor; CFSE, carboxyfluorescein diacetate succinimidyl-
ester; 
 
  
 
m
 
, mitochondrial transmembrane potential; PI, propidium iodide;
SpA, protein A of 
 
Staphylococcus aureus
 
; TUNEL, terminal deoxynucleoti-
dyl transferase-mediated dUTP nick end labeling; Z-VAD, Z-Val-Ala-
Asp(OMe)-fluoromethyl ketone.T
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binds Fc
 
  
 
(2). Moreover, the V
 
H 
 
surface on BCR targeted
by SpA has been conserved in the B cell repertoires of am-
phibian, avian, and mammalian species (3), and is highly
represented in the human and murine immune systems.
In the mouse, Fab-mediated SpA-binding interactions
are commonly displayed by 5–10% of mature B cells,
which express genes from the clan III set of related V
 
H 
 
fam-
ilies, the murine homologues of human V
 
H
 
3 genes (4, 5).
BCR encoded by clan III/S107 V
 
H 
 
genes convey high af-
finity binding activity for SpA (for review see 1). Our stud-
ies of the consequences of in vivo exposure have shown
that SpA can deplete V
 
H
 
-targeted B cells in both neonates
and adult mice by a process that is unimpaired in
TCR
 
  
 
 
 
/
 
  
 
mice, indicating that T cells are not required
(6). Exposure also results in an associated proportional loss
of S107-
 
  
 
transcripts and clan III V
 
H
 
-encoded circulating
IgM and Ab responses whereas other responses are unaf-
fected (5, 6).
Among the SpA-targeted clan III/S107-encoded clones
are B cells bearing the T15 idiotype (6). T15 lymphocytes,
which reside within the B-1 pool, display high affinity
SpA-binding activity and are depleted after in vivo expo-
sure (6). Because these T15 B-1 cells dominate responses to
phosphorylcholine-containing immunogens, their loss after
in vivo exposure to SpA explained the finding of induced
phosphorylcholine-specific immune tolerance. In fact, this
long-term immunologic impairment in SpA-treated mice
persists despite the fact that central neo-lymphogenesis re-
establishes the level of newly formed S107-expressing B
cells in the periphery within 1–2 wk after the last SpA
treatment (5). In explanation, the effect of SpA treatment
on Ig transcript levels was found to be complex. The
persistent selective loss of S107 transcripts in the spleen
correlated with an induced persistent “hole” in the B-1
repertoire and resulting depletion of splenic spontaneous
S107-IgM–secreting cells that subsequently cannot be re-
plenished from the central compartment (6, 7).
Although we have postulated that SpA exposure leads to
BCR-mediated cell death, the underlying process has not
been examined. We could not formally rule out alternative
mechanisms that include the induction of a “suppressive”
regulatory circuit, nondeletional functional inactivation
(i.e., anergy) accompanied by sIg down-regulation that im-
pairs in vivo detection, or a trafficking event that removes
the affected clan III V
 
H 
 
gene–expressing B cells from the
sites of investigation.
In these studies, to investigate the mechanism(s) respon-
sible for the supraclonal lymphocyte loss, we have evalu-
ated the outcome of in vivo exposure to this B cell toxin
on affected lymphocytes. These studies elucidate the se-
quence of events that follows SpA exposure from the sur-
face phenotypic changes induced on V
 
H
 
-restricted BCR-
expressing B cells to the induction of apoptosis.
 
Materials and Methods
 
Mice and Immunogens.
 
Mice were obtained from The Jack-
son Laboratory and bred under specific pathogen-free condi-
 
tions under the supervision of the University California San Di-
ego Animal Subjects Program. Adult mice, at least 6 wk of age,
received either recombinant 0.5 mg SpA (RepliGen), 0.5 mg of
a control protein, OVA (Sigma-Aldrich), or 2 mg anti-Ig (H
and L chain specific; Jackson ImmunoResearch Laboratories),
or as indicated, with removal of contaminating endotoxin
(
 
 
 
0.5 EU/ml). Mice received protein in 125 
 
 
 
l of pyrogen-
free saline instilled into the peritoneal cavity. After mice were
killed, tissues were harvested for immediate ex vivo analysis and
aliquots were placed in culture. Mice were age and sex matched
in all experiments.
 
Genomic PCR Southern Surveys of V
 
H
 
DJ Family Expression.
 
To evaluate the effect of treatment on B cell representation,
6-wk-old C57BL/6J mice received a dose of 1 mg protein in sa-
line, which was repeated after 3 d, and were killed 6 d after the
first dose. Freshly isolated splenocytes were purified on a ficoll
gradient and genomic DNA was extracted using a DNeasy Tissue
Kit (QIAGEN) with an RNase incubation step. For amplification
of genomic rearrangement, DNA aliquots of 90, 30, or 10 ng
were added to separate tubes containing 5 
 
 
 
l 10
 
 
 
 PCR buffer
(PerkinElmer), 2 
 
 
 
l of 10 mM dNTP (PerkinElmer), 1 
 
 
 
l of each
50-pmol oligonucleotide primer solution (MWG Biotech), and 1
 
 
 
l Amplitaq gold (PerkinElmer), with nuclease-free H
 
2
 
O added
to a final volume of 50 
 
 
 
l. Samples in triplicate were amplified
using a denaturing step of 95
 
 
 
C for 12 min, 32 cycles of 95
 
 
 
C for
30 s, 60
 
 
 
C for 30 s, and 72
 
 
 
C for 40 s, followed by a final 72
 
 
 
C
for 5 min. To amplify V
 
H 
 
family–specific rearrangement, reac-
tions were performed with a framework 1–derived oligonucle-
otide primer specific for members of the J558 family (clan I) or
S107 family (clan III) primer paired with an antisense J
 
H
 
-derived
primer as previously described (5, 8). Products were electro-
phoretically separated, transferred to membranes, and hybridized
with digoxigenin-labeled (Roche), V
 
H 
 
family–specific 150–250-bp
exon-derived DNA probes, and later reacted with peroxidase-
tagged antidigoxigenin Ab before visualization of bands with
ECF substrate (Amersham Biosciences) with images analyzed as
previously described (5). To independently confirm the V
 
H 
 
fam-
ily specificity of the amplification reactions, aliquots were also
subcloned into the TA system (Invitrogen) and sequence was de-
termined (6 and unpublished data).
 
Flow Cytometry Analysis.
 
Adapting previously reported meth-
ods (3, 5, 6), mononuclear cells were stained with FITC-labeled
anti-CD21 (clone 7G6), CD40 (clone HHM40-3), CD54 (clone
3E2), CD69 (clone H1.2F3), CD80 (clone 16-10A1), CD86
(clone GL-1), CD95 (clone JO-2), TRI-COLOR
 
®
 
-labeled anti-
CD19 (clone 6D5; Caltag), biotin-labeled I-A
 
b 
 
(clone KH74),
PE- or biotin-labeled mSpA, or isotype controls used with
streptavidin-labeled Per CP
 
® 
 
or APC (BD Biosciences) in the
presence of Fc block (BD Biosciences) as appropriate. Data was
acquired using a FACSCalibur™ (Becton Dickinson) and ana-
lyzed with FlowJo™
 
 
 
software (Treestar, Inc.). Forward and side
scatter gates included only nucleated viable cells, dead cells were
excluded based on light scatter, and propidium iodide (PI) or
7-AAD uptake as possible.
To measure the activity of a pro-apoptotic pathway, cells were
permeabilized and stained with specific affinity-purified rabbit
IgG anti-activated caspase 3 (Cell Signaling Technology) and de-
tected with PE goat anti–rabbit IgG (Southern Biotechnology
Associates, Inc.). Alternatively, DNA fragmentation was deter-
mined by the terminal deoxynucleotidyl transferase-mediated
dUTP nick end labeling (TUNEL) assay (Roche) and changes in
mitochondrial transmembrane potential (
 
  
 
m
 
) were detected by
staining with JC-1 (Intergen Company; reference 9).T
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Histology.
 
Spleens were placed in OCT compound embed-
ding media (Fisher Scientific) and frozen in a 2-methylbutane/dry
ice bath. 7-
 
 
 
M sections were cut and mounted on Superfrost
Plus Slides (Fisher Scientific). Slides were fixed in 3.7% formalde-
hyde in PBS, pH 7.4, for 20 min at room temperature, blocked
in PBS, 5% FCS for 1 h at room temperature, and then stained
with either PE-labeled anti-B220 or anti-CD3 (diluted in block-
ing buffer), washed, permeabilized with 0.1% Triton X-100 in
0.1% sodium citrate for 2 min on ice, washed, and then stained
with the TUNEL assay kit (Roche). After mounting with Pro-
long (Molecular Probes), digitized images were captured at 
 
 
 
10
or 
 
 
 
40.
 
Adoptive Transfer Studies.
 
Isolated splenocytes were suspended
at 5 
 
  
 
10
 
7
 
/ml in RPMI, labeled with 1 
 
 
 
M carboxyfluorescein
diacetate succinimidylester (CFSE; Molecular Probes), and incu-
bated at 37
 
 
 
C for 10 min. The cells were washed three times in
ice cold RPMI with 5% FCS and resuspended in PBS. A total of
3 
 
  
 
10
 
7 
 
splenocytes were transferred intravenously through the
tail vein. After 24 h, mice received either SpA or control protein
as described above, or 500 
 
 
 
g of the immunostimulatory CpG
phosphorothioate oligonucleotide (5
 
  
 
TGA CTG TGA ACG
TTC GAG ATG A 3
 
 
 
), which was used as a positive control for
proliferation (i.e., mitogen; reference 10). Control studies con-
firmed that CFSE treatment did not compromise the ability of B
cells to respond to SpA or mitogens (unpublished data).
 
In Vitro Stimulation Studies.
 
In certain studies, freshly isolated
splenocytes were placed in culture of 5% CO
 
2 
 
in RPMI with 5%
FCS, supplemented with 
 
l
 
-glutamine, 10 mM Hepes, amino acid
solution, 1 mM sodium pyruvate, 60 
 
 
 
M 
 
 
 
-mercaptoethanol,
and penicillin/streptomycin at 2 
 
  
 
10
 
6 
 
cell/ml at 37
 
 
 
C. In some
studies, B cells were first enriched by magnetic negative selection
(StemCell Technologies Inc.) to attain 
 
 
 
92% B220
 
  
 
cells. In
other studies, freshly isolated cells were first labeled with 5 
 
 
 
M
CFSE, washed twice in IMDM, and placed in culture for 72–96 h
as described above, with or without various stimulants: 10 
 
 
 
g/ml
 
Escherichia coli
 
 LPS (Sigma-Aldrich), 10 ng/ml IL-4 (BD Bio-
sciences), or 5 ng/ml soluble mCD40L-mCD8
 
  
 
fusion ligand
(provided by P. Lane, University of Birmingham, Birmingham,
UK; reference 11) cross-linked with 5 
 
 
 
g/ml rat anti–murine
CD8 (53-6.72; BD Biosciences). To assess the role of the caspase
pathway, splenocytes were cultured with 25 
 
 
 
M of the pan-cas-
pase inhibitor, Z-Val-Ala-Asp(OMe)-fluoromethyl ketone
(Z-VAD) or control compound and buffer alone according to
the manufacturer’s directions (Enzyme Systems Products).
 
Statistical Analysis.
 
Comparisons between different groups
used the two tailed Student’s 
 
t
 
 test with P values of 
 
 
 
0.05 taken
as significant.
 
Results
 
SpA Induces Loss of Genomic S107 Rearrangements.
 
In
earlier reports, we have demonstrated that in vivo treat-
ment of mice with SpA leads to a rapid loss of detectable
SpA-reactive B cells in both the peripheral and central
compartments, with the lowest levels occurring 
 
 
 
4–6 d af-
ter exposure (5). We also found that in vivo exposure re-
sults in a concurrent selective depletion of splenic S107-
 
 
 
transcripts whereas 
 
  
 
transcripts from other V
 
H 
 
families
were unaffected (6). The persistent selective loss of S107
transcripts after SpA exposure was interpreted as a reflec-
tion of the special immunobiology of B-1 cells and sponta-
neous IgM-secreting cells (6, 7). These findings, however,
also suggest that splenic transcript levels may not be the best
marker of the magnitude of supraclonal B cell deletion.
To address concerns that the tolerizing properties of
SpA may derive in part from cellular regulatory effects on
Ab gene transcription, we assessed the outcome of in vivo
SpA exposure on the representation of genomic S107 rear-
rangements in the spleen, which should avoid a bias for
detection of cells with disproportionately higher content
of Ab gene transcripts. The results from these PCR-based
assays were also normalized for content of J558 (clan I) ge-
nomic rearrangements. As shown in Fig. 1, SpA treatment
of adult C57BL/6 mice resulted in a greater than a sixfold
reduction of the amplimers of genomic S107 rearrange-
ments. Furthermore, because this assay also detects the
nonproductive V
 
H 
 
genes that represent 
 
 
 
15% of adult
splenic S107 rearrangements (Feeney, A., personal com-
munication), these findings likely underestimate the level
of V
 
H
 
-selective B cell loss in the periphery induced by
SpA with sequential treatments. These results provide in-
dependent confirmation that in vivo exposure can result in
the selective cellular deletion of a large supraclonal set of
S107-expressing lymphocytes, which is targeted based on
V
 
H 
 
region expression.
 
SpA Modulates the Surface Phenotype of B Cells Targeted for
Deletion.
 
To begin to elucidate the process by which SpA
induces the deletion of B cells, we evaluated the response
of T15i Ig “knockin” mice, in which almost all B cells ex-
press an S107 transgene that conveys the high affinity V
 
H
 
framework-associated SpA-binding motif (2). In these
studies, 1 mg SpA in buffered saline was instilled into the
Figure 1. In vivo SpA exposure results in a selective loss
of genomic S107 rearrangements. C57BL/6 mice received
control or SpA intraperitoneal treatment. Each VH family–
specific blot included amplifications of the serial amounts
of genomic DNA. As illustrated, the amount of genomic
template is indicated above the resultant blot, with relative
values normalized by densitometric quantitation using the
J558 rearrangements shown below.  , a positive control of
a S107 gene–containing plasmid;  , a negative control of a
J558 gene–containing plasmid. The data are representative
of two independent studies of two mice in each group that
used JH1- or JH2-specific antisense primers.T
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peritoneum and mice were killed at intervals to survey for
subsequent induced changes. 2 h after treatment, we first
detected down-regulation of surface Ig on splenic T15i
transgene–expressing (B220
 
 
 
) B cells (unpublished data).
Beginning at 4 h after treatment, sequential increases in the
representation of T15i V
 
H
 
-expressing B cells were demon-
strated in the spleen. In untreated T15i
 
 
 
/
 
  
 
mice, the total
number of mononuclear splenocytes was 62 
 
  
 
10
 
6 
 
  
 
4.4
(mean 
 
  
 
SEM) with 45 
 
  
 
2.2% B cells whereas at 4 h after
treatment both the total number of splenocytes and the
representation of B cells increased to 82 
 
  
 
10
 
6 
 
  
 
8.5 and
50 
 
  
 
0.7%, respectively. A further increase was observed at
12 h after treatment with 96 
 
  
 
10
 
6 
 
  
 
4.8 splenocytes and
58   0.7% B cells whereas at 16 h we found 92   106  
4.8 splenocytes and 51    5.0% B cells. As these early
changes began so rapidly, and cell cycle analysis failed to
detect significant induced proliferation after these brief pe-
riods of exposure (unpublished data), we therefore believe
this in part reflects altered trafficking into the spleen.
In vivo SpA exposure also induced a concurrent comod-
ulation of other B cell surface molecules. As illustrated in
Fig. 2 A, 16 h after in vivo instillation, the B cells from the
Figure 2. Phenotypic changes of the initiation phase and cell death in-
duced in splenic T15i /  B cells. (A) SpA induces down-regulation of
membrane-associated BCR, CD19, and CD21 on splenic T15i /  B cells
at 16 h after treatment. Based on staining for CD19 or B220, SpA treat-
ment was shown to result in an increased representation of B lymphocytes
in the spleen at this time point. Panels depicted were first gated based on
B220 expression (a). Studies depicted were from a different experiment
than in other panels (b). (B) In vivo SpA exposure induces an activation
phenotype on T15i /  B cells. Shaded regions depict results after treat-
ment with control protein and those from SpA-treated mice are indicated
by the bold line. Values are indicated for mean intensity of fluorescence,
with significant difference indicated by *. For these studies, nonviable
cells were gated out based on scatter and PI uptake. Results are also de-
picted after in vitro culture of splenocytes for different periods, as indi-
cated. (C) SpA treatment induces accelerated loss of splenic T15i /  B
cells after in vitro culture. Panels depict the representation of splenic B
cells in samples obtained at time of harvest (ex vivo, 16 h) from mice that
received 0.5 mg OVA or SpA, or 2 mg of anti-Ig, and after sequential pe-
riods in culture in the absence of additional stimulants. In each panel, the
total number of B cells (boxed numbers) was determined for a total of
15,000 viable (i.e., PI ) mononuclear cells. The data are representative of
three experiments.T
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SpA-treated T15i /  mice displayed reduced levels of sIgM
and sIgD and also the BCR coreceptor, CD19. Levels of
CD21 were also reduced (probably as it acts as a receptor
for complementized SpA; 12). In contrast, levels of B220 (a
CD45 isoform) were unaffected (Fig. 2 A), which is consis-
tent with reports that B220 is not comodulated after in
vitro anti-IgM treatment (13).
Splenic B cells from treated T15i /  mice were also
evaluated for other induced phenotypic changes. As illus-
trated in Fig. 2 B, when harvested 16 h after in vivo expo-
sure, B cells from SpA-treated mice displayed increased
levels of CD69 and CD86 (top), which have previously
been described as early markers of specific B cell activation.
After sequential periods in culture without additional stim-
ulants, surface expression of these molecules peaked and
then waned whereas levels of CD80 and CD95 were
shown to increase at later time points (Fig. 2 B) with up-
regulation of CD40, CD54, and MHC II (Fig. 3 C; un-
published data). In general, B cell phenotypic changes in-
duced by in vivo SpA exposure reiterate the patterns first
described to occur after in vitro stimulation with experi-
mental BCR ligand analogs (14) or antigenic exposure.
Time course analyses of cellular loss of VH-targeted B
lymphocytes from these T15i /  mice demonstrated that
after only 16 h of in vivo SpA exposure more than half of
these B cells were fated for cell death, which progressed
during the subsequent 48 h of in vitro culture as deter-
mined by PI staining (Fig. 2 C). By contrast, after in vivo
treatment with anti-Ig, far fewer (only  10%) of B cells
were fated to die. Hence, despite their early removal from
the SpA- or anti-Ig–treated host, these B cells were still
committed to a fate of activation-associated accelerated
cell death (Fig. 2 C). These observations are consistent
with findings that the overwhelming majority of VH-sus-
ceptible B cells are depleted after 4–6 d of repeated in vivo
SpA doses (5 and unpublished data). Cellular death in-
duced by SpA was most pronounced in B cells with the
most down-regulated levels of sIg (unpublished data).
Equivalent findings were also documented in studies of
splenic B cells that were enriched by negative selection be-
fore in vitro culture (unpublished data). Significantly, akin
to findings from an in vivo model system that used anti-
IgD as a surrogate Ag (14), we could not detect evidence
of induced B cell loss in the spleen in surveys at or before
16 h after in vivo SpA administration.
To confirm that these induced phenotypic changes oc-
curred only on SpA-binding B cells, equivalent treatment
studies were performed in hemizygotic T15i mice (i.e.,
T15i / ) that have two distinct mature B cell populations.
In these mice, only  30% of splenic B cells express the T15
VH region linked to the IgMa allotype. In the remainder of
T15i /  B cells, this transgene has been inactivated by sec-
ondary recombination, leading to diverse endogenous VH
rearrangements distinguished by the IgMb allotype (15).
When the SpA-treated T15i hemizygotic mice were
evaluated after in vivo challenge, only the IgMa-bearing B
cells that express the S107 transgene–encoded VH region
had a marked down-regulation of surface Ig (Fig. 3 A). In
contrast, in these same samples no global changes were de-
tected for the levels of membrane-associated IgMb that ex-
press predominantly nonsusceptible VH regions (Fig. 3 B).
Flow cytometric surveys demonstrated the IgMa-bearing B
cells from SpA-treated T15i /  mice displayed the same se-
quential induction of markers of lymphocyte activation. At
Figure 3. VH-susceptible
splenic B cells in adult T15i / 
mice undergo induced pheno-
typic changes after in vivo SpA
exposure. (A) After treatments as
described in Fig. 2, at 16 h after
in vivo exposure sIg levels on
IgMa-bearing T15i /  B cells are
greatly depressed after SpA treat-
ment but not control treatment.
(B) sIg levels on IgMb-bearing
splenic B cells from these mice
are unaffected. (C) Levels of sur-
face molecules associated with
activation of splenic mononu-
clear cells gated on B220 are de-
picted for Ig transgene–linked
IgMa-bearing B cells. (D) Levels
of these surface molecules are
demonstrated for splenic B cells
bearing IgMb, which identifies
the endogenous polyclonal B
cells in the same samples. Here,
results are shown for CD86,
CD54, and MHC II for splenic
B cells at time of harvest whereas
the results for CD80 and CD40 are depicted after an additional 24 h in culture. Results after treatment with control protein are shaded and those from
SpA-treated mice are indicated by the bold line. Mean intensity of fluorescence values are indicated. For these studies, nonviable cells were gated out
based on scatter and PI uptake. The data are representative of three experiments.T
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time of harvest 16 h after in vivo exposure, there were in-
creased levels of CD86, CD54 (ICAM-1), and MHC II on
IgMa-bearing B cells from SpA-treated mice (Fig. 3 C)
compared with the IgMb-bearing B cells from the same
mice (Fig. 3 D). After an additional 24 h in culture, levels
of CD80 and CD40 were significantly elevated on IgMa-
bearing B cells from the SpA-treated T15i /  mice (Fig. 3
C). By comparison, although SpA treatment did not induce
generalized changes on the splenic IgMb-bearing B cells, a
small proportion (i.e.,  10%) of the IgMb-bearing B cells
from SpA-treated mice were found to have up-regulated
their surface MHC II (Fig. 3 D). Furthermore, after an ad-
ditional 24 h in culture we also detected an increase in
CD80 expression on this small subset of IgMb-bearing B
cells from these mice (Fig. 3 D). In explanation, this minor
subpopulation of IgMb-bearing B cells is at the same fre-
quency that we have previously documented for the ex-
pression of SpA-binding clan III VH regions among the
polyclonal B cells in C57BL/6 mice (5, 6).
Taken together, these studies indicate that in vivo expo-
sure to SpA specifically targets certain B cells based on VH
usage. This results in the induction of a phenotype of
down-regulated BCR and associated cellular activation
with later progression to the triggering of an intracellular
death pathway.
In Vivo Clonal Fate after SpA Treatment. To assess di-
rectly the in vivo fate of susceptible B cells after SpA treat-
ment and determine whether exposure induces B cell pro-
liferation, T15i /  splenocytes were labeled with CFSE
and adoptively transferred into congenic C57BL/6 recipi-
ents (16). As illustrated in Fig. 4, at 48 h after treatment,
transferred T15i /  B cells recovered from the spleens of
SpA-treated recipient mice were found to have undergone
up to two to three rounds of proliferation whereas there
was no evidence of proliferation in splenocytes from con-
trol-treated mice. Significantly, despite this evidence of
proliferation, in this experiment there was still a mean 36%
decrease of B cells in the SpA-treated T15i /  mice com-
pared with the control-treated mice (P    0.015). By
contrast, there was a mean 173% increase of T15i /  B cells
in the spleens of the mitogen-treated mice (Table I). In the
LNs of these SpA-treated mice there was a  58% mean re-
duction of T15i /  B cells compared with control-treated
mice (Fig. 4; unpublished data). Analysis of a similar group
at 96 h after SpA treatment demonstrated an even greater
loss (i.e., mean 54% deletion) in the spleen compared with
control-treated mice (P    0.01; Table I). Intracellular
staining studies for IgMa provided independent confirma-
tion of the same relative levels of deletion (unpublished
data). These studies document that although some prolifer-
ation was induced by SpA, it was insufficient to replace the
B cells targeted for in vivo deletion.
The effect of SpA treatment was also evaluated at other
sites in the peripheral immune system, which demonstrated
that after 6 d the absolute numbers of B cells were similarly
reduced in the spleen, peripheral LNs, mesenteric LNs, and
Peyer’s patches (i.e., mean 68–88% loss; Fig. 5). We also
found a comparable reduction in B220high B cells in the
Table I. Outcome of In Vivo Treatment after Adoptive Transfer
T15i   →C57BL/6
48 ha
T15i   →C57BL/6
96 h
T15i   →Faslgld
48 h
Treatment B:Tb Percent  c B:T Percent   B:T Percent  
Total cells
control 0.61   0.05 — 0.71   0.08 — 1.2   0.1d —
SpA 0.39   0.04 ↓36 0.32   0.04 ↓54 0.6   0.07 ↓45
mitogen 1.7   0.005 ↑173 1.7   0.4 ↑138 2.5e ↑108
Progenitor cells
control 0.6   0.05 — NAf — 1.3   0.2 —
SpA 0.28   0.04 ↓54 NA — 0.5   0.09 ↓57
mitogen 1.4   0.08 ↑133 NA — 2.5 ↑92
aThe number of hours of in vivo exposure to SpA, OVA (control), or CpG (mitogen).
bThe B:T ratio of isolated T15i    splenocytes was unchanged from that found in control-treated mice. In the CFSE-labeled cells, the relative loss of
transferred B cells was determined after various durations in vivo using the assumption that the T cell population remains unchanged in all treatment
groups. There was no evidence of T cell proliferation.
cIndicates the percentage change, either increase (↑) or decrease (↓), compared to the control-treated group whose value is 100%.
dAdoptive transfer of labeled T15i    splenocytes resulted in reconstitution of distinct and reproducible B:T ratios in different untreated/control-
treated immunodeficient strains (unpublished data).
eEach group contains n   3 with this exception in which n   1. Otherwise, mean values   SEM are shown for each group. To estimate the num-
ber of original transferred cells (i.e., progenitor cells) that survived treatment, calculations were based on the evaluation of sequential rounds of pro-
liferation, as previously described (reference 66), using the equation: Progenitor cells   Round 0   (Round 1/2)   (Round 2/4)   (Round 3/8).
fNA, not applicable as proliferation/daughter cells were not discernible.T
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1131 Goodyear and Silverman
bone marrow (5 and unpublished data) whereas there were
no significant differences in the absolute numbers of T cells
at any of these sites (unpublished data). The representation
of B cells was also reduced in the blood, liver, and lung
(i.e., mean 78–85% loss; Fig. 5), which further suggested
that SpA-induced B cell depletion was unlikely to repre-
sent redistribution or sequestration.
Mechanisms of Apoptotic Death Induced by SpA. To char-
acterize the intracellular mechanism(s) responsible for
SpA-induced B cell deletion, we looked for induction of
pathways of programmed cell death and first evaluated the
levels of cellular DNA fragmentation in targeted B cells
using the TUNEL assay, which detects DNA 3 -hydroxyl
ends resulting from caspase-activated DNA cleavage (17,
18). We found that in T15i /  spleens, B220  TUNEL 
apoptotic bodies were deposited in B zones of primary fol-
licles 48 h after SpA treatment (Fig. 6, A–D) and these
B220  apoptotic bodies were also detected in the B zones
in the peripheral LNs, mesenteric LNs, and Peyer’s
patches (unpublished data). These apoptotic bodies ap-
peared to be excluded from the T zones (Fig. 6 B and un-
published data). The highest frequencies were detected at
48 h after SpA treatment with decreased representation at
72 h, and these apoptotic bodies were barely detectable at
96 h (unpublished data).
Studies of T15 /  splenocytes harvested 16 h after in
vivo SpA exposure demonstrated the same viability and ab-
sence of TUNEL staining as splenocytes from control-
treated mice. However, after 24 h in culture, these B cells
from SpA-treated mice displayed a rapid progression of
DNA fragmentation, which was significantly greater than
in B cells from control-treated mice or in the non-B cells
in the same culture (unpublished data). These in vitro
changes progressed with kinetics comparable to those doc-
umented for SpA-induced in situ deposition of B cell ap-
optotic bodies in peripheral lymphoid tissues (Fig. 6, A–D,
and unpublished data).
Next, we looked for involvement of the caspase path-
way, which are cysteine proteases that play a central role in
apoptotic death systems. Akin to the TUNEL studies, we
found that immediately after 16 h of in vivo exposure, lev-
els of activated caspase 3 were not altered in B220  spleno-
cytes cells from SpA-treated T15i /  mice (unpublished
data). However, after the placement in culture, we found
Figure 4. In vivo clonal fate after SpA treatment.
T15i /   splenocytes were labeled with CFSE and
adoptively transferred into congenic C57BL/6 recipi-
ents. Here, CFSE identifies mononuclear cells derived
from the T15i /  donor and dilution of staining inten-
sity identifies cells that have undergone cell division. B
cells are identified as B220 . The in vivo outcome to
treatments with OVA (control), SpA, and immuno-
stimulatory DNA (mitogen) are depicted in cells re-
covered from the spleens and LNs. Mean values for B
cell deletion ( ) or proliferation ( ) in treatment
groups compared with control mice are indicated and
determined as described in Table I. The data are repre-
sentative of three experiments.
Figure 5. The representation of B cells at various
lymphoid and nonlymphoid sites after SpA treat-
ment. Adult T15I /  mice were treated on days 0
and 4, harvested on day 6, and evaluated by flow
cytometry. The percentage of viable B and T cells
in the mononuclear compartment were derived by
B220 and CD3 staining, and B/T ratios were cal-
culated to estimate the percentage change (an indi-
cation of B cell deletion). a, the mean absolute
number   SD of B cells at each site where n   3; b,
the P values derived from the absolute number of B
cells for spleen, peripheral LNs, mesenteric LNs
(MLN), and Peyer’s patches (PP); c, P values de-
rived from the mononuclear percentages for blood,
lung, and liver samples.T
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1132 Death by B Cell Superantigen
Figure 6. Apoptotic pathways induced in VH-susceptible T15i /  B cells during the deg-
radation phase that follows in vivo treatment with SpA. At time of harvest (48 h ex vivo),
there is evidence of increased DNA fragmentation detected by the TUNEL assay (green) in
B cells from T15i /  mice that received SpA (B and D) compared with control (A and C).
A and B were stained with B220 and C and D were stained with CD3 (red). (E) After in
vivo treatment of Fas ligand–deficient (gld) or congenic (C57BL/6) mice that received
CFSE-labeled T15i /  splenocytes, at 48 h the intracellular levels of activated caspase 3 are
greatly enriched in susceptible B cells (i.e., B220 ) from SpA-treated mice (bold line) com-
pared with those receiving control treatment (shaded). By contrast, differences are not seen
in non-B cells (i.e., B220 ). Panels depict data gated on CFSE  events (refer to methods in
Table I). (F) Results are depicted for cytometric assays of   m. Splenic B cells are identified by gating on B220  cells or T cells by CD3  staining.
Herein, the dissipation of   m is identified based on increased shift in FL-1 and lower levels of staining with the specific fluorescent dye detected in FL-2.
Results of splenic lymphocytes are depicted for mice that received SpA treatments at 0, 4, 8, 16, 48, and 72 h before they were killed. (G) The caspase
pathway contributes to SpA-induced apoptotic B cell death. After 16 h of in vivo exposure, splenocytes from control or SpA-treated T15i /  mice were
placed in culture with or without a general caspase inhibitor, Z-VAD. After in vitro culture, although the VH-susceptible B cells from SpA-treated mice
undergo accelerated apoptotic death after an additional 24 h in culture, compared with those from control (OVA) mice, the addition of the caspase inhib-
itor enhances the survival of SpA-exposed T15i-expressing splenic B cells. The data are representative of three or more experiments.T
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1133 Goodyear and Silverman
that intracellular activated caspase 3 levels progressively in-
creased in the SpA-treated B cells in parallel with the en-
hanced induction of DNA fragmentation. Moreover,
throughout the 72-h culture period, these levels increased
at a much greater rate in the B cells from SpA-treated
T15i /  mice, which also were found to rapidly progress to
cytolysis (unpublished data).
To verify that these findings accurately reflect the path-
way of in vivo death in VH-targeted B cells, the same stud-
ies were performed after adoptive transfer of CFSE-labeled
T15 /  splenocytes into C57BL/6 recipients. As shown in
Fig. 6 E, at 48 h after treatment, compared with B cells in
control-treated mice and non-B cells in SpA-treated mice,
the levels of intracellular activated caspase 3 were signifi-
cantly increased only in the T15i /  B cells of SpA-treated
mice.
To further dissect the temporal relationship between B
cell triggering and the induction of the death pathways, we
also surveyed for induced changes in mitochondrial mem-
brane potential that reflect the early phase of the “intrinsic”
apoptosis pathway. As shown in Fig. 6 F, compared with
splenic B cells from an untreated T15i /  mouse, at 4 and
8 h after SpA treatment, differences in   m were already de-
tectable in B cells and much greater proportions of affected
B cells were detectable at 16–48 h (Fig. 6 F and unpublished
data). By 72 h the percentage of affected B cells greatly de-
creased, but this likely in part represented the in vivo clear-
ance of apoptotic B cells. We also found that T15i / 
splenic B cells, harvested 4–24 h after in vivo SpA exposure
and when subsequently placed in culture, demonstrated
these same progressive increases in   m compared with
lymphocytes from control-treated mice (unpublished data).
To investigate the relationship between these different
induced apoptotic pathways, we directly tested the contri-
bution of caspase-dependent mechanisms to the sequence
of events that leads to cellular deletion by repeating the
16-h ex vivo/in vitro survival studies with the inclusion of
Z-VAD, a potent pan-caspase inhibitor (Fig. 6 G). As ex-
pected, Z-VAD had no effect on the cell death of primary
splenocytes that naturally occurs in vitro. However, when
examined after 24 h in culture, Z-VAD enhanced the sur-
vival of the SpA-targeted T15i /  B cells to a level indis-
tinguishable from that of B cells from control-treated mice,
blocking the accelerated DNA fragmentation that reflects
the action of caspase-activated DNase (unpublished data).
The B cells from SpA-treated mice, however, still displayed
the same induced loss of   m (unpublished data). Notably,
when evaluated after 48 h and later times in culture, com-
pared with the rapid apoptotic death that occurred in the
absence of the inhibitor, there was still an accelerated (al-
beit slower) loss of viability for the B cells from SpA-
treated mice cultured with the caspase inhibitor (unpub-
lished data). Although this is consistent with evidence that
Z-VAD does not prevent all death pathways leading to cy-
tolysis (19, 20), these findings indicate that there is not an
absolute requirement for a caspase pathway for induction
by SpA of mitochondrial changes that lead to accelerated
cell death.
Factors that Rescue B Cells Targeted by SpA. To better
understand the mechanism(s) responsible for the loss of the
SpA-targeted T15i /  B cells, we evaluated how their fate
in culture would be affected by supplemental stimulants. As
illustrated in Fig. 7 A, when harvested after 16 h of in vivo
exposure to SpA, we confirmed that there was an acceler-
ated loss of viable T15i VH-expressing B cells in the ab-
sence of an additional factor in culture. After 72 h in cul-
ture, this represented an 82% relative depletion of these B
cells (i.e., from 46% of mononuclear cells at ex vivo harvest
to 8% of residual splenic mononuclear cells after culture).
In contrast, B cells from the control-treated mouse dis-
played only a 46% decrease (i.e., from 37 to 20% of mono-
nuclear cells). In cultures containing LPS, a type I thymus-
independent mitogen, a pronounced B cell pro-survival
effect was demonstrated for B cells previously exposed to
SpA. Significantly, pro-survival effects of SpA were also
demonstrated in cultures that contained either soluble
CD40L or IL-4. In addition to significantly enhancing the
survival of B cells from SpA-treated T15i /  mice, cultur-
ing with these latter stimulants also normalized sIg levels on
responding B cells (Fig. 7 A).
To determine if the increased representation of B cells in
these cultures was in part due to enhanced survival or
whether it reflected enhanced proliferation, we repeated
these studies with splenocytes labeled with CFSE before
placement in culture (16). As illustrated in Fig. 7 B, after
only 16 h of in vivo exposure, when labeled splenocytes
were placed in culture for 72 h without the addition of
stimulants, neither B cells from control- nor SpA-treated
mice displayed evidence of proliferation. In contrast, prolif-
eration was induced by the addition of any of these stimu-
lants. Significantly, between each of these paired cultures,
more B cells from the SpA-treated mice underwent prolif-
eration (and fewer also remained without a single round of
proliferation). Of special interest, although CD40L was
generally much more effective than IL-4 at driving B cell
proliferation, with the inclusion of either of these stimu-
lants, the B cells from SpA-treated mice also appeared to
have more rapid initiation and progression of proliferation
(Fig. 7 B and unpublished data). Although in earlier studies
we showed that SpA-induced deletion is unimpaired in T
cell–deficient mice (6), the current findings document that
targeted B cells can be rescued by high local levels of the B
cell pro-survival factors, IL-4 and CD40L, which are natu-
rally provided by helper T cells. It also shows that although
a large proportion of B cells display mitochondrial mem-
brane permeabilization at 16 h (Fig. 6 F), the in vitro addi-
tion of a second signal results in greatly enhanced survival
and proliferation, suggesting that at this early time point
mitochondrial membrane changes may not inevitably lead
to B cell death.
Bcl-2 Overexpression Blocks SpA-induced B Cell Death.
In other systems the pro-survival influence of Bcl-2 has
been shown to oppose apoptotic signals affecting the mito-
chondrial pathway (21). To determine whether overex-
pression of Bcl-2 can affect the cellular fate of B cells trig-
gered by SpA, we challenged TgN (Bcl-2)22 transgenicT
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1134 Death by B Cell Superantigen
mice (22) and compared their responses to those of con-
genic BALB/c mice (Fig. 8). Although in these mice only a
limited percentage of their polyclonal peripheral B cells ex-
press VH genes conveying susceptibility to SpA ( 5%), the
fate of these targeted B cells can be readily monitored (3, 5,
6). Reiterating earlier findings, when examined after 16 h
of SpA exposure there were significant decreases in the
proportion of splenic B cells with detectable Fab-mediated
SpA-binding activity in mice from both strains (Fig. 8),
which reflected SpA-induced depression of sIg levels that
was limited to affected B cells (unpublished data). After an
additional 96 h in culture, compared with splenic B cells
from the control-treated BALB/c mice that included 5.0  
0.7% (mean   SD) SpA-reactive B cells, B cells from SpA-
treated BALB/c mice exhibited a significant deletion (62%)
with only 1.9   1% of residual SpA-reactive B cells (P  
0.004). Although showing the same trend, compared with
the representation in control-treated Bcl-2 transgenic mice
(5.6   1.3%), a smaller percentage of splenic SpA-reactive
Bcl-2 transgenic mice B cells (28%) were deleted after SpA
treatment (4.1   0.8%; P   0.06). Comparisons also dem-
onstrated that SpA exposure resulted in a significantly
greater deletion of SpA-reactive B cells in the BALB/c
than in Bcl-2 transgenic mice (P   0.0095). Hence, the
current data indicate that overexpression of Bcl-2 impairs
the induction of apoptotic cell death in B cells exposed in
vivo to SpA. These findings most likely reflect the interfer-
ence by Bcl-2 overexpression on the threshold for the in-
duction of death pathways that first affects   m.
Apoptotic B Cell Death Does Not Require the Fas Death Re-
ceptor. Although the data described above implicate the
mitochondria-associated “intrinsic pathway” in the B cell
death induced by SpA, there is also extensive evidence that
“death receptors” and most notably Fas, can be involved in
the regulation of clonal expansion after certain types of B
cell activation (for review see 23). However, when CFSE-
labeled T15i /  splenocytes were adoptively transferred
into Faslgld mice (in which a mutation has inactivated the
Fas ligand; 24), we found that there was no impairment in
the efficiency of SpA-induced death in Fas-deficient mice
(Table I). Moreover, in surveys of apoptotic pathways,
comparable levels of activated caspase 3 were induced after
SpA treatment of Fas ligand–deficient mice compared with
control mice (Fig. 6 E), and there were also no significant
differences detected by the TUNEL assay (unpublished
data). To also assess the functional outcome of exposure,
BALB/c FasLlpr/lpr mice (in which a mutation has inacti-
vated the Fas receptor; 25) and control groups of six mice
received 1 mg SpA or control protein and then were as-
sessed 1 mo later. The results from ELISPOT studies of
Figure 7. Supplemental factors can rescue B cells from death and induce enhanced proliferation. Splenocytes from T15i /  mice were analyzed 16 h
after treatment (ex vivo) and culture with or without additional stimuli. (A) After 72 h in culture, the B cells affected by SpA (i.e., IgMa bearing) display
increased representation after in vitro culture with CD40L or IL-4. (B) Results are depicted following the same experimental design, except that the ex
vivo splenocytes were labeled with CFSE and then placed in culture for 72 h. As shown, after gating on IgMa-bearing B cells, cells that have not under-
gone a single round of proliferation display the highest intensity of fluorescence (i.e., CFSE high) whereas after each round of proliferation the fluores-
cence is decreased. The bar graphs depict the percentage of cells that have undergone proliferation. Solid bars depict SpA treated and open bars represent
B cells from control treated. After culture with CD40L or IL-4, there were no significant differences in the number of total mononuclear cells recovered
from the OVA- or SpA-exposed cell cultures. The data are representative of three experiments.T
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1135 Goodyear and Silverman
SpA-treated Fas-deficient mice reiterated values deter-
mined from previous studies in BALB/c and C57BL/6
mice (5, 6), demonstrating that in vivo SpA exposure in-
duced similar long-term depletion of splenic SpA-reactive
IgM-secreting cells in both Fas-sufficient and Fas-deficient
mice (unpublished data). Taken together, the data indicate
that the Fas ligand/receptor pathway is not required for the
induction of apoptotic supraclonal B cell death by SpA.
Discussion
In these studies we have investigated the mechanisms by
which protein A of S. aureus acts as a natural B cell toxin to
induce the programmed cell death of susceptible VH-tar-
geted B cells. We found that apoptotic B cell death in-
duced by SpA has three distinct phases (Fig. 9; reference
26). During the initiation phase, which begins shortly after
infusion, there is a rapid down-regulation of surface Ig.
Within a few hours this is followed by an up-regulation of
surface phenotypic markers of activation on the B cells des-
tined for deletion. These up-regulated B cell surface mole-
cules included CD40, CD95, and MHC II, which have
been implicated in interactions with T cells. There is also
evidence of induced rapid dissipation of   m in the tar-
geted B cells.
The outcome of the decision phase is seen after 36–48 h
of in vivo exposure when the rapid dissipation of   m in
the targeted B cells may eventually lead to the activation of
DNases and the “point of no return” (27). However, our
in vitro studies suggest that during the decision phase this
clonal fate can be aborted by addition of the T cell factors,
IL-4 or CD40L (refer to Fig. 7).
The subsequent degradation phase is associated with a
full induction of catabolic hydrolases, leading to the activa-
tion of caspase 3 and the caspase-associated DNase respon-
sible for TUNEL staining. Cumulatively, from the time of
initial exposure, SpA-induced VH-targeted cellular deletion
progressed to completion over 4–6 d (5, 6).
Our studies detected SpA-induced mitochondrial changes
after only 4 h whereas induction of activated caspase 3 was
not detected until  16 h after treatment. Confirming that
this BCR-mediated cell death pathway involves separate
but sequential phases of induced death, we found that cul-
ture of in vivo–exposed B cells in the presence of the pan-
caspase inhibitor, Z-VAD, prevented the induction of both
the caspase pathway and TUNEL  DNA fragmentation
whereas the in vitro progression of   m was unaffected.
These findings, akin to those from recent in vitro B cell
stimulation studies (28), document the caspase indepen-
dence of the mitochondrial effector phase of this induced
death process. Also consistent with this model, we found
that the in vivo overexpression of Bcl-2 hindered the
apoptosis-specific degradation phase associated with the
SpA-induced deletion. These findings therefore document
yet another system for which certain Bcl-2 members, which
are inserted into the outer mitochondrial membrane, appear
to maintain mitochondrial integrity and prevent apoptosis
by suppressing mitochondrial membrane permeabilization
(22). The overexpression of Bcl-2 may also interfere with
this BCR-mediated death by decreasing the rise in calcium
after activation. Hence, these findings confirm the early and
central role of mitochondria (and perhaps the ER) in this
BCR-mediated death process induced by SpA.
The apoptotic pathways demonstrated for SpA-induced
B cell deletion reflect features previously reported for acti-
vation-induced cell death (AICD) that in other settings has
Figure 8. Effect of Bcl-2 overexpression on SpA-induced B cell dele-
tion. The outcome of in vivo treatments with SpA or a control protein
are depicted for Bcl-2 transgenic (TgN(Bcl-2)22) and BALB/c mice.
When evaluated ex vivo, 16 h after treatment, SpA exposure greatly de-
creases the representation of detectable SpA-reactive B cells in either
strain of mice. After subsequent in vitro culture, SpA exposure results in
the deletion of most of the SpA-reactive BALB/c B cells whereas compa-
rable deletion does not occur in the Bcl-2 transgenic B cells. Analyses
were performed on groups of OVA-treated BALB/c mice (n   5), SpA-
treated BALB/c mice (n   6), OVA-treated Bcl-2 transgenic mice (n  
5), and SpA-treated Bcl-2 transgenic mice (n   4).
Figure 9. Mechanisms of death induced by a B cell superantigen. En-
counter of susceptible B cells with pentameric natural SpA is mediated by
a nonimmune interaction with BCR that include clan III VH regions. (1)
During the initiation phase, this encounter results in down-regulation of
BCR and the coreceptors that include CD19 and CD21, and the induc-
tion of activation markers (not depicted). (2) A decision phase, lasting
many hours follows subsequently, during which B cells might be rescued
by second signal. (3) The degradation phase is presumably mediated by
the apoptosome, with release of cytochrome C, and eventually leading to
the apoptotic caspase-dependent death pathways.T
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1136 Death by B Cell Superantigen
been posited to be the cause of lymphocyte death initiated
by engagement of the Ag receptor. Studies of Ig transgenic
mice have shown that B lymphocytes, especially centro-
cytes in a germinal center response, die in response to
stimulation by soluble Ag with insufficient BCR cross-
linking properties (29–32). This process is believed to re-
flect physiologic mechanisms for maintaining peripheral
tolerance, as it enables newly generated self-reactive cells
to be deleted after encounter with their specific auto-Ag
(30, 33, 34). Akin to our findings, in vitro studies using
human Burkitt’s lymphoma cell lines, believed to be repre-
sentative of germinal center B cells, are also sensitive to
apoptosis induced by soluble anti-IgM Abs (35–38) due to
the activation of caspase 3 (39, 40). Indeed, anti-IgM–induced
apoptosis in lymphoma cell lines is reported to also be ini-
tiated at the mitochondrial level by a caspase-independent
induced loss of   m and cytochrome c release, that only
later leads to the execution of apoptosis (39). Overexpres-
sion of Bcl-2 has been shown to also render Burkitt’s cell
lines and germinal center B cells resistant to BCR-medi-
ated apoptosis in vitro (39, 41–44) and in vivo (45). Studies
of cell lines have suggested that arrest of cell cycle progres-
sion contributes to B cell AICD (46, 38). Overall, our
findings are consistent with evidence from in vitro B cell
systems in that there is a distinct temporal sequence of
events after certain pro-apoptotic death stimuli, in which
the mitochondrial pathway is affected before the induction
of pro-apoptotic caspases and DNases.
Adoptive transfer studies demonstrated that 48 h of in
vivo exposure to SpA induced a limited level of in vivo
proliferation (Fig. 4) that we did not detect in the spleno-
cytes cultured after only 16 h of in vivo exposure (Fig. 7
B). We postulate that in the former the proliferation was
detectable either because of the more prolonged period of
in vivo exposure to SpA, or due to the in vivo influence of
cytokine and/or cognate help from other bystander mono-
nuclear cells. Despite this induced proliferation, at 48 h af-
ter in vivo treatment there was still a mean 36% loss of
T15i /  splenic B cells in SpA-treated mice. We also enu-
merated the remaining sets of B cells from each sequential
round of proliferation to estimate the number of transferred
B cells from which they derived (i.e., progenitors; Table I).
This indicated that SpA treatment deleted 54% of the trans-
ferred T15i /  progenitors (P   0.0017). By comparison,
analogous studies have shown that the T cell superantigen,
staphylococcal enterotoxin B, induced a much more vigor-
ous period of in vivo proliferation, which peaked at an
 66% increase in the representation of susceptible T cells
at 72 h after treatment, and apoptotic T cell deletion only
followed after a discrete number of cell divisions (47).
Hence, although in vivo exposure to either type of super-
antigen can induce proliferation of the lymphocytes tar-
geted for death, the proliferative response to this staphylo-
coccal B cell superantigen is far more limited than has been
reported for a staphylococcal T cell superantigen.
In studies of B cell lines, the BCR-mediated apoptotic
pathway has been shown to be independent of the CD95
and TNF-R death receptor systems (38, 39) that have been
implicated in the AICD pathways of peripheral CD4  and
CD8  T lymphocytes (48; for review see 23). In our inves-
tigations, although other death domain signaling pathways
were not examined, we did confirmed that SpA-induced
deletion was unimpaired in Fas-deficient mice (Fig. 6 E).
We also found that SpA induced the same death pathways
as were induced by in vivo treatment with anti-Ig in the
same systems, although the latter was far less efficient (Fig.
2 C and unpublished data). Therefore, our studies confirm
that the B cell death pathway induced by SpA is the same
as that induced by BCR triggering, which is distinct from
that reported to be initiated by Fas triggering (49).
Extending our earlier evidence that deletion is unim-
paired in TCR  -deficient mice (6), our demonstration of
the rescue of SpA-targeted B cells by IL-4 (or CD40L) is
also in agreement with comparable recent studies in hen
egg lysozyme double transgenic mice (50). From a classical
perspective, this clearly indicates that the process of SpA-
induced B cell deletion embodies features predicted for the
“two signal” model (51) in which an “imbalance” of these
signals leads to lymphocyte death. To provide a biologic
context for this finding, in an earlier point we demon-
strated that naive mice do not mount a T cell response to
SpA but immunization with small doses of SpA in adjuvant
can induce specific T cell sensitization with a frequency of
responder T cells comparable to that associated with other
conventional protein Ags (5). Even a robust SpA-specific T
cell response is orders of magnitude lower than the very
high frequency of B cells targeted for death by SpA. Based
on the cumulative findings, we wonder whether a SpA-
specific conventional T cell response would be sufficient to
affect the fate of a substantial number of the B cells targeted
by SpA. However, the outcome of SpA exposure may also
be different during staphylococcal infection when T cell
superantigens might be coexpressed.
The nature of the VH-targeted BCR-binding interaction
of SpA conveys special features that are well suited for the
induction of cell death. The immunobiologic properties of
SpA are aided by its oligovalent structure, as this secreted
membrane protein contains five homologous Ig-binding
domains in tandem, and although the native pentameric Ig-
binding protein (or even a tetramer) displays deletional
properties, we have previously shown that a monomeric
form does not (6). In solution, the 42-kD native SpA mol-
ecule takes on an extended structure and in every SpA
molecule there are at least two accessible Fab-binding sites
capable of micromolar binding interactions. In vitro studies
have suggested that due to apparent affinity thresholds and
differences in effective valency, certain anti-IgM reagents
might be more effective at inducing BCR-mediated apop-
tosis (52). In vivo, the activities of infused Ab-based anti-Ig
agents can be greatly impaired by interactions with circulat-
ing Ig (Finkelman, F., personal communication). By com-
parison, the actual in vivo BCR ligand that forms after SpA
infusion might be quite complex, as intravenous adminis-
tration of SpA rapidly results in the formation of high mo-
lecular weight complexes with IgG, which can persist for at
least 24 h in the circulation (53), and our recent in vitroT
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studies suggest that the interactions of SpA with VH-tar-
geted B cells may in fact be enhanced by the presence of
soluble Ig (unpublished data). We speculate that the nature
of these in vivo–formed complexes may facilitate signal
spreading (for review see 54) that contributes to the in vivo
deletional properties of SpA. The different properties of the
effective in vitro SpA complex or the inclusion of addi-
tional stimulants may explain the very different outcome
previously reported for in vitro stimulation with SpA prep-
arations, which are reputed to instead convey pro-survival
(i.e., anti-apoptotic) effects for VH-susceptible human pe-
ripheral B cells (55, 56). This may reiterate lessons learned
from studies of the properties of potential anti-lymphoma
Ab agents, as the outcome of in vitro studies of BCR-tar-
geted agents, like SpA, may not be an accurate predictor of
in vivo biologic activity (57).
Although they are believed in general to be less vulnera-
ble than B cell precursors to negative selection, mature B
cells have also been shown to undergo deletion after in
vitro (38, 40, 58, 59, 60) or in vivo (14) treatment with ex-
perimental anti-Ig reagents. Therefore, we attempted to
determine whether VH-targeted B cells within distinct pe-
ripheral subpopulations might be differentially affected by
in vivo SpA exposure. Instead, we found that SpA rapidly
induced changes in essential phenotypic markers that inter-
fered with our first attempts to make meaningful quantita-
tive measurements of the effects on defined B cell subsets
(such as conventional follicular B cells or the CD21hi mar-
ginal zone B cells; Fig. 2). In any case, the genomic rear-
rangement surveys documented a  85% loss of susceptible
B cells (Fig. 1) and transcript and cellular analyses have
shown comparable or even greater levels of induced dele-
tion (5–7). The cumulative evidence, therefore, indicates
that most immature and peripheral mature B cells, includ-
ing follicular B cells (5), B-1 cells (6, 7), and marginal zone
B cells (unpublished data) that bear high affinity VH clan III
BCR, are susceptible to SpA-induced deletion.
Although the central features are concordant with those
revealed in earlier studies of BCR-mediated negative se-
lection of B lymphocytes, here we have characterized the
outcome of in vivo exposure to a natural toxin that in-
duces death in B lymphocytes via targeting of a conserved
surface on the VH region. In general, apoptosis is accepted
to be important for controlling the size of lymphocyte
populations and maintaining homeostasis within the im-
mune system, as it occurs during lymphopoiesis and during
antigenic challenges, contributing to the maintenance of
self-tolerance and the specificity of immune responses (29,
61). These studies demonstrate that SpA acts by co-opting
these physiologic pathways of BCR-mediated apoptotic
pathways, and we have recently shown that this can result
in the induction of immunologic tolerance (5, 6). These
mechanisms are therefore not unique to SpA, but are
likely also common to other BCR-targeting toleragens,
from those reported in the earliest studies of parenteral
administration with anti-Ig reagents (14, 62) to anti-
idiotypic Abs (63) and other experimental antigenic sys-
tems (64).
In conclusion, these studies extend evidence that SpA
has properties with many parallels with those of bacterial
and viral proteins classified as superantigens for T cells. In
addition, these data also provide an example in which SpA
can be used to elucidate the special cellular and molecular
pathways of B lymphocytes, and to better understand their
roles in the regulation of host immunity. Furthermore, this
prototypic B cell superantigen may also have the same af-
fect in the human immune system, for which the invariant
VH3-encoded SpA binding site is represented on up to half
of all mature B lymphocytes (for reviewed see 1), as recent
studies indicate that clan III VH-expressing primate B cells
are also susceptible to SpA (65). Therefore, now armed
with an understanding of these underlying principles, we
postulate that SpA, or analogs, may also prove useful in
therapeutic interventions designed to target the B cells that
mediate certain diseases.
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